Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified Aβ Peptides. - Wikidata - awgldk - TriplyDB

Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified Aβ Peptides.

Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified Aβ Peptides.

http://www.wikidata.org/entity/Q30315438

about

Fibrils of Truncated Pyroglutamyl-Modified Aβ Peptide Exhibit a Similar Structure as Wildtype Mature Aβ Fibrils Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways.Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure.Pyroglutamate-Modified Amyloid β (11- 40) Fibrils Are More Toxic than Wildtype Fibrils but Structurally Very Similar.N-Terminally Truncated Amyloid-β(11-40/42) Cofibrillizes with its Full-Length Counterpart: Implications for Alzheimer's Disease.Remarkable Modulation of Self-Assembly in Short γ-Peptides by Neighboring Ions and Orthogonal H-Bonding.Purification of recombinant Aβ(1-42) and pGlu-Aβ(3-42) using preparative SDS-PAGE.

P2860

Q28829500-B74BC496-4911-4A52-A64F-353946A70FFF Q42363417-1477C19F-2DB0-4033-B151-1D244C5AF7F5 Q46404042-DCE8615E-A611-41AE-B9FB-1D8EFB622E1F Q48132995-80AC97B7-D24D-4A87-9ADE-F18827565A1B Q48284125-EB6268E5-D672-4B28-AAEC-29CC1971A5EE Q48313483-3371895F-884A-4268-AC16-AFCC96C016C0 Q50641687-F63A5A3A-E8E9-4166-BDC5-0E7F8073F6AA

P2860

Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified Aβ Peptides.

http://www.wikidata.org/entity/Q30315438

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@ast

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@en

type

label

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@ast

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@en

prefLabel

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@ast

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@en

P1433

Q30315438-3967B4B0-7D0D-4609-9C94-C1A44BAAF725

P1476

Q30315438-4D09A468-F744-4787-9F62-304DFF97CCE8

P2093

Q30315438-00D57F56-6C05-4E66-BD77-798B487DD9D6

Q30315438-21E09509-E8E7-46D2-9D8B-1508EE860856

Q30315438-4F67CF4E-9976-4141-9BB3-185F0A5BD11A

Q30315438-521E855F-4DC6-45A3-A63E-F124FBD04E9E

Q30315438-52811961-EBB7-41A6-A23D-BC2541418BB7

Q30315438-7348F17E-C5E0-46EC-B387-C5D9CEFD232A

Q30315438-8B55C847-1E91-4BCA-B160-C2F80A156844

Q30315438-BC96426B-75B9-40CB-8E1C-234A3A494442

Q30315438-E0DA277D-400F-47B7-98A3-F0097886C6E9

Q30315438-E5A5F989-5AB1-462C-A2AC-47FAD50BC0F0

P2860

Q30315438-08ADE03A-9B3E-41E6-9F98-3B35845422A9

Q30315438-1FCD52F4-8E76-4C90-8FF9-6DE4436E50F0

Q30315438-21E9E249-E165-4DF1-8A66-539267529F8C

Q30315438-38055697-B0C9-4A1E-806B-2BFADEB35E71

Q30315438-3A9C477D-BDD8-4BB5-BC7B-0D75DDA3951D

Q30315438-55CA2652-D61C-471C-AC66-F1B99BB27750

Q30315438-5794E686-83D4-4E9E-82EF-D6A7E6483ACC

Q30315438-64A0A5B3-7539-46DF-950C-150A1700EECD

Q30315438-689ED87A-A5E1-4C9F-A2C9-D5A45B4920A3

Q30315438-71DD2EEC-3B9E-4BA8-9E9F-3E1EBE2C0A25

P304

Q30315438-FE22FFBD-AA9C-4867-87A1-1090EA32AB4C

P31

Q30315438-533955F0-2EDA-42DD-916F-6C5C5B948AAC

P356

Q30315438-F35029AC-AB56-47F1-862C-7425AA9E89DE

P407

Q30315438-CA7EBC63-2431-43D2-8D9B-86808097D8D9

P433

Q30315438-90D57761-5CA2-4264-A355-8F127A757559

P478

Q30315438-43DB8E8F-28EE-4C79-96DF-498DE44CFA9D

P50

Q30315438-67A1AA69-D7E1-4EB7-8EB5-D8BFB56608F2

P577

Q30315438-88098BE6-A1DB-4456-9612-B4DBF82A551E

P698

Q30315438-095160A0-1BB6-45C8-A37D-48CE7892BC86

P356

P1433

Angewandte Chemie International Edition

P1476

Enhanced Fibril Fragmentation ...... glutamyl-Modified Aβ Peptides.

@en

P2093

Angelika Schierhorn

http://www.w3.org/2001/XMLSchema#string

Anka Thümmler

http://www.w3.org/2001/XMLSchema#string

Dagmar Schlenzig

http://www.w3.org/2001/XMLSchema#string

Hans-Ulrich Demuth

http://www.w3.org/2001/XMLSchema#string

Jay K Yadav

http://www.w3.org/2001/XMLSchema#string

Jens-Ulrich Rahfeld

http://www.w3.org/2001/XMLSchema#string

Liesa Heinrich

http://www.w3.org/2001/XMLSchema#string

Marcus Fändrich

http://www.w3.org/2001/XMLSchema#string

Melanie Wulff

http://www.w3.org/2001/XMLSchema#string

Monika Baumann

http://www.w3.org/2001/XMLSchema#string

P2860

3D structure of Alzheimer's amyloid-beta(1-42) fibrils

Structural basis of β-amyloid-dependent synaptic dysfunctions.

Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides.

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach.

An analytical solution to the kinetics of breakable filament assembly.

The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation.

Paired beta-sheet structure of an Abeta(1-40) amyloid fibril revealed by electron microscopy

Kinetic intermediates of amyloid fibrillation studied by hydrogen exchange methods with nuclear magnetic resonance.

P304

5081-5084

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANIE.201511099

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26970534

http://www.w3.org/2001/XMLSchema#string